| Title |
Recent Advances in the Pharmacotherapy of Infantile Spasms
|
|---|---|
| Published in |
CNS Drugs, February 2014
|
| DOI | 10.1007/s40263-014-0139-5 |
| Pubmed ID | |
| Authors |
Raili Riikonen |
| Abstract |
Adrenocorticotrophic hormone (ACTH), oral corticosteroids and vigabatrin are now first-line treatments for infantile spasms in the US and Europe. There is now increased knowledge regarding the role of ACTH, corticosteroids and vigabatrin (e.g. efficacy, doses, side effects, treatment in specific aetiological subtypes of infantile spasms), and other antiepileptic drugs (i.e. topiramate, valproate, zonisamide, sulthiame, levetiracetam, lamotrigine, pyridoxine, ganaxolone), as well as adjunctive flunarizine and novel drugs not yet in clinical use for infantile spasms (i.e. pulse rapamycin and melanocortin receptor agonists). The existence of a latent period, weeks to months following a precipitating brain insult, raises the possibility of preventive interventions. Recent experimental data emerging from animal models of infantile spasms have provided optimism that new and innovative treatments can be developed, and knowledge that drug treatment can affect long-term cognitive outcome is increasing. The aim of this article is to review recent developments in the pharmacotherapy of infantile spasms and to highlight the practical implications of the latest research. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Denmark | 1 | 1% |
| Peru | 1 | 1% |
| Unknown | 68 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 17% |
| Student > Bachelor | 9 | 13% |
| Other | 8 | 11% |
| Student > Ph. D. Student | 8 | 11% |
| Student > Master | 6 | 8% |
| Other | 16 | 23% |
| Unknown | 12 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 48% |
| Neuroscience | 7 | 10% |
| Agricultural and Biological Sciences | 6 | 8% |
| Psychology | 3 | 4% |
| Immunology and Microbiology | 1 | 1% |
| Other | 6 | 8% |
| Unknown | 14 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2022.
All research outputs
#6,929,526
of 22,721,584 outputs
Outputs from CNS Drugs
#626
of 1,304 outputs
Outputs of similar age
#83,677
of 307,144 outputs
Outputs of similar age from CNS Drugs
#13
of 22 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,304 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,144 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.